Journal List > Ann Lab Med > v.39(1) > 1100938

TOOLS
Erratum: Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea
Erratum

Annals of Laboratory Medicine 2019; 39(1): 113.

Published online: 13 September 2018

DOI: https://doi.org/10.3343/alm.2019.39.1.113

Erratum: Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea

© The Korean Society for Laboratory Medicine

The Korean Society for Laboratory Medicine

(open-access):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
This erratum is being published to correct the company errors on the article “Delamanid, Bedaquiline, and Line zolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resis tant and Extensively Drug-resistant Tuberculosis in Korea” Ann Lab Med 2018;38(6):563-8 https://doi.org/10.3343/alm.2018.38.6.563
Before correction:
Page 564:
2. Anti-TB drugs
Delamanid powder was obtained from Otsuka Pharmaceutical (Tokyo, Japan), bedaquiline powder was obtained from Janssen Pharmaceutica (Beerse, Belgium), and linezolid was supplied by Yungjin Pharmaceutical (Seoul, Korea).
After correction:
Page 564:
2. Anti-TB drugs
Delamanid powder was obtained from Otsuka Pharmaceutical (Tokyo, Japan) and Advanced ChemBlocks Inc (Burlingame, CA, USA). Bedaquiline powder was obtained from Janssen Pharmaceutica (Beerse, Belgium) and Advanced ChemBlocks Inc (Burlingame, CA, USA). Linezolid was supplied by Yungjin Pharmaceutical (Seoul, Korea).
TOOLS
Similar articles